STERIS Acquired Xodus Medical for $2.1 Billion
The acquisition adds specialized operating room consumables to the STERIS product portfolio.
Updated on Oct. 12, 2026 in Healthcare
Live Poll
Do you trust that further consolidation of medical device companies improves the safety of your care?
STERIS Corporation has signed a definitive agreement to acquire Xodus Medical for a gross purchase price of $2.1 billion. The transaction, expected to close by the end of 2026, aims to expand the acquirer's footprint in the operating room consumables market.
Why it matters
By adding Xodus Medical's portfolio, STERIS seeks to bolster its top-line growth and adjusted earnings margins through expanded product offerings. The move reflects a broader industry strategy of scale-building to secure recurring revenue in specialized hospital supplies.
STERIS expects a net purchase price of approximately $1.8 billion after accounting for $300 million in projected cash tax benefits. The deal includes up to $150 million in potential earnout consideration tied to 2028 performance metrics for Xodus Medical.
The players
STERIS Corporation
A global provider of infection prevention and surgical products for healthcare and life sciences sectors.
Xodus Medical
A manufacturer of operating room safety and consumables headquartered in Pennsylvania.
The details
The transaction will be financed primarily through debt to acquire all equity of the Pittsburgh-based company. Once finalized, the integration will combine Xodus Medical's established operating room consumables with the existing supply chain of STERIS. The deal is structured to be accretive to margins, assuming the acquired business hits its target of $135 million in adjusted EBIT for 2026.
Timeline
1993: Xodus Medical was founded.
October 12, 2026: STERIS announced the acquisition agreement.
December 31, 2026: Expected closing date of the transaction.
2028: Performance period for the potential $150 million earnout.
Market Landscape
This deal follows the established pattern of major medical device companies using large-scale debt-financed acquisitions to absorb specialized niche manufacturers. Such moves reflect the ongoing consolidation trend in medical device manufacturing that continues to reshape the supply chain for healthcare operators.
Operators should anticipate potential shifts in supply contracts and pricing models as the companies integrate their portfolios. Procurement teams should monitor internal communications from both vendors to identify changes in product availability or procurement lead times through 2026.
The takeaway
Large-scale acquisitions of niche medical suppliers often trigger shifts in account management and product bundling policies. Keep a close watch on your current supply contracts for potential renegotiation triggers as the transition approaches its December 2026 close date.
Further reading
For more on market trends, see the latest analysis in Healthcare.
Live Poll
Do you trust that further consolidation of medical device companies improves the safety of your care?
